FEATURED EDITORIAL
Next-generation sequencing (NGS) has allowed the industry to uncover all aspects of genomic activity, including the 98% of the traditionally unexplored genome, now known as the regulatory genome. Let's explore RNA as "digital software" for drug development, a look beyond NGS, and the role of long-coding RNAs in particular.
- An Overview Of The 9 FDA Special Designations for Pipeline Drugs
- 4 Major Trends In Lipid Nanoparticle Research
- Cautious Optimism For Biotechs And Their Outsourcing Partners
- How Can We Approach Cell And Gene Therapy To Treat MS?
- Respiratory Viral Infections: The Next Frontier For Antiviral Drug Development
- Genomics: The 2 Biggest Trends & An Unbiased Look At Vendors
- Navigating The Murky Waters Of Patent Claims Involving AI After Amgen v. Sanofi
FEATURED APPLICATION CONTENT
-
Review the capabilities and robustness of a new single-use fermenter in a fast, exponentially growing, high cell density Escherichia coli (E. coli) process.
-
Discover a modeling approach employing artificial neural networks (ANNs) using experimental factors combined with simulation-derived parameters plus viscosity data from 27 highly concentrated (180 mg/ mL) mAbs.
-
During the manufacture of sterile products, process control is essential. Here, we explore the role of filtration for bioburden control in quality risk management and contamination control strategies, EU GMP Annex 1, and more.
-
The existing regulatory system is ambiguous for RNA therapeutics. Leverage this Investigational New Drug (IND) guide to help accelerate and strengthen the process IND filing of novel nanomedicines.
-
Analyze the cost distribution over time for autologous CAR T therapy manufacturing using process economics and insights from scientists and R&D. Discover how cell therapy manufacturers can combat these costs.
-
Despite the momentum of the RNA-LNP therapeutic market, significant manufacturing challenges remain in the development of RNA-based vaccines and therapeutics. Learn how NxGen™ mixing can solve three key challenges.
-
Explore results from a resin lifetime study with over 150 cycles, using clarified cell harvest in every cycle, which has been performed to evaluate the alkaline stability of three protein A resins.
-
Discover a protein L affinity chromatography resin that is well suited for use in biomanufacturing and offers increased binding capacities compared to other resins.
-
In this study, we used mechanistic modeling to investigate how AAV-resin interactions are affected when MgCl2 is used as an elution additive.
-
A step-by-step high-throughput process development (HTPD) workflow to determine the optimal resin and initial conditions for hydrophobic interaction chromatography (HIC).
-
In this study, we looked at how different antibody binding sites of a protein A ligand are affected by cleaning in place (CIP).
-
Discover a novel approach for manufacturing chemically defined media with precision control of trace impurities that utilizes innovative raw material analysis, data analytics, and a proprietary algorithm.
FEATURED NEWS HEADLINES
- Twist Bioscience And IMIDomics Collaborate To Discover Antibodies For Applications In Immune-Mediated Inflammatory Diseases
- Viatris And Ocuphire Pharma Announce FDA Approval Of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops For The Treatment Of Pharmacologically-Induced Mydriasis Produced By Adrenergic Agonists Or Parasympatholytic Agents
- Ono Enters Into A Drug Discovery Collaboration Agreement With Adimab To Discover Novel Antibody Drugs In The Oncology Field
- Chrysalis Receives FDA Approval To Initiate Clinical Trials With Chrysalin (TP508)
- Phathom Pharmaceuticals Announces Vonoprazan NDA Submission For Non-Erosive GERD
- FDA Accepts Defender Pharmaceuticals’ New Drug Application For Intranasal Scopolamine Gel
- ABM Therapeutics' ABM-1310 Granted Fast Track Designation By The FDA Following Orphan Drug Designation
- Novo Nordisk And Evotec Collaborate To Launch LAB eN², A Translational Drug Discovery Accelerator, To Address Innovation Gap In Cardiometabolic Diseases
- Pierre Fabre Laboratories And Vernalis Announce A Drug Discovery Collaboration In Oncology
- Drug Discovery On An Unprecedented Scale
ARCHIVED NEWSLETTER
- 09.26.23 -- Improve The Efficiency And Productivity Of Biologics Manufacturing
- 09.26.23 -- Using AI In Drug Discovery Isn't The Golden Solution You Think It Is — Yet
- 09.25.23 -- Improve Your Productivity With The Use Of Effective Modular Systems
- 09.20.23 -- Enhancing Medicines In Development: A Patient- And Planet-Centric Approach
- 09.19.23 -- Protein Degraders: Progress, Limitations, & Future Directions